AbbVie (ABBV)
(Delayed Data from NYSE)
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $197.53 -0.02 (-0.01%) 8:50 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $197.53 -0.02 (-0.01%) 8:50 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Key Predictions for Q3 Earnings Reports of ABBV, MRK
by Zacks Equity Research
The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.
Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod
by Arpita Dutt
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.
Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength
by Zacks Equity Research
Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.
Healthcare ETFs Set to Soar as Q3 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, healthcare ETFs are set to soar.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics
by Zacks Equity Research
AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
by Zacks Equity Research
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
Where to Find Value in Healthcare Stocks
by Tracey Ryniec
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
by Zacks Equity Research
J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.
Cancer Space Update: Lung & Breast Cancer Studies in Focus
by Zacks Equity Research
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?
by Zacks Equity Research
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
by Arpita Dutt
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Here's What's Has Happened in the HCV Space Lately
by Zacks Equity Research
A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.
AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.
Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.
Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?
by Arpita Dutt
With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.
Merck Drops Two HCV Combination Programs Amid Competition
by Zacks Equity Research
Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.
Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China
by Zacks Equity Research
Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.